Get the Stockscreener App
157.21
1.46%
-2.33
Guardant Health Inc stock is traded at $157.21, with a volume of 2.56M.
It is down -1.46% in the last 24 hours and down -1.81% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$159.54
Open:
$157.93
24h Volume:
2.56M
Relative Volume:
0.97
Market Cap:
$21.10B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-46.23
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
-6.69%
1M Performance:
-1.81%
6M Performance:
+49.94%
1Y Performance:
+160.45%
1-Day Range:
$156.21
$159.71
1-Week Range:
$156.21
$171.92
52-Week Range:
$53.40
$176.58
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
157.21 | 22.16B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A - Stock Titan
Guardant Health Insider Sold Shares Worth $7,645,218, According to a Recent SEC Filing - Yahoo Finance
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate - MarketBeat
Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells $7,645,056.00 in Stock - MarketBeat
Guardant Health CPO Monroe sells $7.6 million in stock By Investing.com - Investing.com Australia
Guardant Health CPO Monroe sells $7.6 million in stock - Investing.com
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $65.06 vs Price $159.54 - GuruFocus
Guardant Health, Inc. $GH Position Increased by Quantinno Capital Management LP - MarketBeat
Guardant Health, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Guardant Health at canaccord growth conference: shield drives growth By Investing.com - Investing.com Canada
GH: Record growth in oncology and screening, with Shield adoption and payer coverage accelerating - TradingView
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million - Yahoo Finance
Guardant Health (GH) Just Gave Investors Something To Think About - Yahoo Finance
Handelsbanken Fonder AB Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health CCO Chris Freeman sells $10.7m in common stock - Investing.com
Chris Freeman Sells 63,605 Shares of Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guardant Health sees strong growth from MRD and screening, boosted by FDA approvals and guideline inclusion. - Pluang
Guardant Health: Screening And MRD Are Just Getting Started (NASDAQ:GH) - Seeking Alpha
Guardant Health grants 46,044 RSUs to 149 new employees under inducement plan - Bitget
Guardant Health (GH) holder plans 63,605-share stock resale - Stock Titan
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
How Guardant Health Inc. (GH) Affects Rotational Strategy Timing - Stock Traders Daily
Guardant Health, Inc. (GH) Stock Analysis: Assessing Growth Potential with a 15.32% Upside - DirectorsTalk Interviews
Empowered Funds LLC Trims Stock Position in Guardant Health, Inc. $GH - MarketBeat
Amundi Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Dimensional Fund Advisors LP Sells 123,826 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
A Look at Guardant Health Inc (GH) After 6.9% Gain -- GF Value $64.74 vs Price $168.48 - GuruFocus
Guardant Health (GH) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 1,700 Shares of Stock - MarketBeat
Guardant Health director Manuel Hidalgo Medina sells $279k in stock - Investing.com
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $64.71 vs Price $157.58 - GuruFocus
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Director Hidalgo Medina Manuel - Moomoo
Guardant Health (NASDAQ:GH) Director Ian Clark Sells 14,180 Shares - MarketBeat
Guardant Health (NASDAQ: GH) insider files to sell 1,700 shares - Stock Titan
Guardant Health (GH) insider files to sell 1,803,685 shares valued at $134M - Stock Titan
Guardant Health (GH) Sees 48% Growth as Its Cancer Tests Gain Momentum - finance.yahoo.com
Janus Henderson Group PLC Increases Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH) insider Ian T. Clark plans potential sale of 14,180 shares - Stock Titan
Rathbones Group PLC Sells 38,606 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. $GH Shares Purchased by California State Teachers Retirement System - MarketBeat
Guardant Health Is Maintained at Buy by Stifel - Moomoo
Guardant Health, Inc. (GH) Stock Analysis: Impressive Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Hamilton Wealth LLC Purchases 38,916 Shares of Guardant Health, Inc. $GH - MarketBeat
Edgestream Partners L.P. Boosts Stock Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Forecasts - Yahoo Finance
Guardant Health Earnings: Shield Momentum Shows No Signs Of Slowing, Guidance Raised Again - Morningstar
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $191.09, Implies 25% Upside - TradingView
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Guardant Health shares rise after strong Q2 growth and higher 2026 outlook - Quiver Quantitative
Guardant Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):